Optimer Teams With AztraZeneca To Bring Dificid To South America
This article was originally published in The Pink Sheet Daily
Executive Summary
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
You may also be interested in...
Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.
Durata Sets Sights On Commercialization As Dalbavancin Nears Filing
After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.
Durata Sets Sights On Commercialization As Dalbavancin Nears Filing
After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.